Due to the observed role of TILs in breast cancer progression, albeit not completely well-defined, and an understanding of the immunoediting hypothesis, several immune checkpoint inhibitors against PD-1, PD-L1 and CTLA-4 have been tested in the treatment of the disease (Rizzo and Ricci, 2022). This evidence concerns the gene CTLA4 and breast carcinoma.